• OSE Immunotherapeutics Expands Collaboration with MAbSilico americanpharmaceuticalreview
    February 05, 2021
    OSE Immunotherapeutics announced a new collaboration agreement with MAbSilico, a deep technology TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.
PharmaSources Customer Service